M-Protein Analysis in Plasma of Multiple Myeloma Patients by Intact Mass Spectrometry

May 4, 2024

Luca Genovesi, Michael Schirm, Nick Dupuis, Gwenael Pottiez

CellCarta’s poster on M-Protein analysis in plasma of multiple myeloma (MM) patients highlights the use of intact mass spectrometry for monitoring disease progression. This non-invasive method, requiring only a small volume of plasma or serum, measures M-Protein levels with high sensitivity, precision, and reproducibility.

The study demonstrated that mass spectrometry could detect significant reductions in M-Protein concentration, providing an effective alternative to bone marrow biopsies for evaluating treatment response and measurable residual disease (MRD). The workflow supports high-frequency sampling, offering a comprehensive profile of disease progression and treatment efficacy in MM patients.

View the poster

M-Protein Analysis in Plasma of Multiple Myeloma Patients by Intact Mass Spectrometry